Rhumbline Advisers increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 427,457 shares of the pharmaceutical company’s stock after purchasing an additional 6,137 shares during the period. Rhumbline Advisers owned approximately 0.17% of Vertex Pharmaceuticals worth $64,991,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Achmea Investment Management B.V. lifted its holdings in shares of Vertex Pharmaceuticals by 68.0% in the 2nd quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock worth $1,116,000 after purchasing an additional 3,507 shares in the last quarter. NorthCoast Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $782,000. Delta Lloyd Asset Management N.V. bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $3,285,000. Prudential Financial Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 12.8% in the 2nd quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock worth $57,312,000 after purchasing an additional 50,350 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 89.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,463 shares of the pharmaceutical company’s stock worth $1,863,000 after purchasing an additional 6,836 shares in the last quarter. Institutional investors own 92.79% of the company’s stock.
In other Vertex Pharmaceuticals news, EVP Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $152.93, for a total transaction of $324,976.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Altshuler sold 1,796 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $160.00, for a total value of $287,360.00. Following the transaction, the executive vice president now directly owns 107,807 shares of the company’s stock, valued at approximately $17,249,120. The disclosure for this sale can be found here. Insiders have sold a total of 220,094 shares of company stock valued at $32,074,719 in the last ninety days. Insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up $0.13 during mid-day trading on Tuesday, reaching $148.16. The company’s stock had a trading volume of 232,273 shares, compared to its average volume of 1,824,147. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The stock has a market cap of $37,616.77, a price-to-earnings ratio of 247.90, a PEG ratio of 3.78 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.16 EPS. sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.
A number of brokerages recently issued reports on VRTX. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Needham & Company LLC restated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Finally, DA Davidson began coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $173.15.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.